Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology
Shots:
- Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further develop and commercialize the develop product
- Anaeropharma has developed APS001F- a recombinant Bifidobacterium expresses Cytosine Deaminase which converts a prodrug- 5-FC- to an anti-cancer drug- 5-FU- is currently evaluated under P-I trial in the US
- Bifidobacterium is an anaerobic- nonpathogenic bacterium existing as enteroflora in the human body. i-DPS technology is designed to deliver B. longum which expresses active molecules specifically at hypoxic disease sites
Ref: Anaeropharma | Image: astellas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com